Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Moderna announces new COVID-19 vaccine supply agreement with Australia » 07:07
05/12/21
05/12
07:07
05/12/21
07:07
MRNA

Moderna

$159.00 /

+0.44 (+0.28%)

Moderna announced a new…

Moderna announced a new supply agreement with the government of Australia for 25M doses. This includes 10M doses of Moderna's COVID-19 vaccine against the ancestral strain to be delivered in 2021 and 15M doses of Moderna's updated variant booster vaccine candidate to be delivered in 2022. Purchase under this agreement is subject to regulatory approval of mRNA-1273 and booster vaccine candidates by the Therapeutic Goods Administration, or TGA, of Australia. The company expects to submit an application to the TGA shortly. As Moderna has continued to scale its commercial network, the company announced earlier this year that it also plans to open a commercial subsidiary in Australia.

ShowHide Related Items >><<
MRNA Moderna
$159.00 /

+0.44 (+0.28%)

MRNA Moderna
$159.00 /

+0.44 (+0.28%)

05/07/21 Barclays
Moderna price target raised to $194 from $178 at Barclays
05/07/21 Goldman Sachs
Moderna price target raised to $228 from $206 at Goldman Sachs
05/06/21 Piper Sandler
Moderna price target lowered to $231 from $234 at Piper Sandler
05/06/21 Needham
Moderna execution 'continues to impress,' but reflected in stock, says Needham
MRNA Moderna
$159.00 /

+0.44 (+0.28%)

  • 19
    May
MRNA Moderna
$159.00 /

+0.44 (+0.28%)

MRNA Moderna
$159.00 /

+0.44 (+0.28%)

MRNA Moderna
$159.00 /

+0.44 (+0.28%)

Tuesday
Periodicals
Takeda may double Moderna imports to hasten Japan vaccination, Reuters reports » 09:22
05/11/21
05/11
09:22
05/11/21
09:22
TAK

Takeda Pharmaceutical

$16.96 /

+0.09 (+0.53%)

, MRNA

Moderna

$158.51 /

-4.63 (-2.84%)

Takeda Pharmaceutical…

Takeda Pharmaceutical (TAK) may double imports of Moderna's (MRNA) COVID-19 vaccine to 100M vaccines in order to accelerate Japan's COVID-19 inoculation efforts, Reuters staff reports, citing statements made by Takeda CEO Christophe Weber during a conference call. "Japan is behind. So our goal now is to really support an acceleration of the vaccination," Weber said, later adding the approval for the larger shipment from the government is expected to come "very soon," according to Reuters. Reference Link

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$16.96 /

+0.09 (+0.53%)

MRNA Moderna
$158.51 /

-4.63 (-2.84%)

TAK Takeda Pharmaceutical
$16.96 /

+0.09 (+0.53%)

04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
MRNA Moderna
$158.51 /

-4.63 (-2.84%)

05/07/21 Barclays
Moderna price target raised to $194 from $178 at Barclays
05/07/21 Goldman Sachs
Moderna price target raised to $228 from $206 at Goldman Sachs
05/06/21 Piper Sandler
Moderna price target lowered to $231 from $234 at Piper Sandler
05/06/21 Needham
Moderna execution 'continues to impress,' but reflected in stock, says Needham
TAK Takeda Pharmaceutical
$16.96 /

+0.09 (+0.53%)

MRNA Moderna
$158.51 /

-4.63 (-2.84%)

  • 19
    May
MRNA Moderna
$158.51 /

-4.63 (-2.84%)

TAK Takeda Pharmaceutical
$16.96 /

+0.09 (+0.53%)

MRNA Moderna
$158.51 /

-4.63 (-2.84%)

TAK Takeda Pharmaceutical
$16.96 /

+0.09 (+0.53%)

MRNA Moderna
$158.51 /

-4.63 (-2.84%)

Monday
Hot Stocks
FDA to hold advisory committee meeting on pediatric COVID vaccine use on June 10 » 12:24
05/10/21
05/10
12:24
05/10/21
12:24
PFE

Pfizer

$40.11 /

+0.54 (+1.36%)

, BNTX

BioNTech

$197.44 /

+13.87 (+7.56%)

, MRNA

Moderna

$158.63 /

-4.51 (-2.76%)

, AZN

AstraZeneca

$54.58 /

+0.78 (+1.45%)

, JNJ

Johnson & Johnson

$170.66 /

+2.02 (+1.20%)

, NVAX

Novavax

$166.90 /

-8.72 (-4.97%)

, INO

Inovio

$6.98 /

+0.14 (+2.05%)

The U.S. Food and Drug…

The U.S. Food and Drug Administration's Center for Biologics Evaluation and Research will convene a virtual meeting of the Vaccines and Related Biological Products Advisory Committee on June 10, 2021, via webcast, to provide a status update on its approach to emergency use authorization for COVID-19 vaccines intended for use in individuals 12 through 17 years of age. The committee will also discuss the data needed to support an EUA and a biologics license application for a COVID-19 vaccine intended for use in children less than 12 years of age. "The committee will not discuss any specific products," the FDA stated. Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research, said: "Vaccines continue to be an important public health measure in fighting the COVID-19 pandemic. To date, the FDA has authorized three COVID-19 vaccines for emergency use that have met our rigorous standards for quality, safety, and effectiveness - two are authorized for individuals 18 and older, and one is authorized for individuals 16 and older. We recognize that the next critical step is having vaccines available for use throughout the pediatric population. As with the initial COVID-19 vaccine authorizations, we want to ensure that the public has a clear understanding of our expectations for the data and information needed to support requests for emergency use authorization and biologics license applications for vaccines intended to prevent COVID-19 in this pediatric age range." Companies with approved COVID-19 vaccines or working on such vaccines include Pfizer (PFE), BioNTech (BNTX), Moderna (MRNA), AstraZeneca (AZN), Johnson & Johnson (JNJ), Novavax (NVAX), Inovio (INO), Vaxart (VXRT) and CureVac (CVAC). Reference Link

ShowHide Related Items >><<
PFE Pfizer
$40.11 /

+0.54 (+1.36%)

NVAX Novavax
$166.90 /

-8.72 (-4.97%)

MRNA Moderna
$158.63 /

-4.51 (-2.76%)

JNJ Johnson & Johnson
$170.66 /

+2.02 (+1.20%)

INO Inovio
$6.98 /

+0.14 (+2.05%)

BNTX BioNTech
$197.44 /

+13.87 (+7.56%)

AZN AstraZeneca
$54.58 /

+0.78 (+1.45%)

PFE Pfizer
$40.11 /

+0.54 (+1.36%)

05/10/21 Morgan Stanley
Pfizer price target raised to $42 from $38 at Morgan Stanley
05/06/21
Fly Intel: Top five analyst downgrades
05/06/21 Mizuho
Pfizer downgraded to Neutral from Buy at Mizuho
05/05/21 JPMorgan
Pfizer price target raised to $40 from $36 at JPMorgan
BNTX BioNTech
$197.44 /

+13.87 (+7.56%)

02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
MRNA Moderna
$158.63 /

-4.51 (-2.76%)

05/07/21 Barclays
Moderna price target raised to $194 from $178 at Barclays
05/07/21 Goldman Sachs
Moderna price target raised to $228 from $206 at Goldman Sachs
05/06/21 Piper Sandler
Moderna price target lowered to $231 from $234 at Piper Sandler
05/06/21 Needham
Moderna execution 'continues to impress,' but reflected in stock, says Needham
AZN AstraZeneca
$54.58 /

+0.78 (+1.45%)

05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/12/21
Fly Intel: Top five analyst downgrades
JNJ Johnson & Johnson
$170.66 /

+2.02 (+1.20%)

05/05/21 Argus
Emergent BioSolutions downgraded to Hold from Buy at Argus
04/29/21 Wells Fargo
Boston Scientific price target raised to $50 from $42 at Wells Fargo
04/26/21 B. Riley
B. Riley reiterates Buy on Novavax, Sell on Arcturus amid vaccine developments
04/19/21 Chardan
Chardan sees J&J moving forward with Emergent if observations are minor
NVAX Novavax
$166.90 /

-8.72 (-4.97%)

03/26/21 B. Riley
Novavax selloff on 'rumored' production delay overdone, says B. Riley
03/12/21 H.C. Wainwright
Novavax price target raised to $317 from $207 at H.C. Wainwright
INO Inovio
$6.98 /

+0.14 (+2.05%)

05/10/21 Piper Sandler
Inovio Phase 2 data for INO-4800 'lackluster,' says Piper Sandler
04/23/21 Oppenheimer
Oppenheimer still bullish on Inovio after U.S. discontinues trial funding
04/23/21 Piper Sandler
Piper 'incrementally cautious' on Inovio, says today's selloff appropriate
PFE Pfizer
$40.11 /

+0.54 (+1.36%)

NVAX Novavax
$166.90 /

-8.72 (-4.97%)

MRNA Moderna
$158.63 /

-4.51 (-2.76%)

JNJ Johnson & Johnson
$170.66 /

+2.02 (+1.20%)

INO Inovio
$6.98 /

+0.14 (+2.05%)

BNTX BioNTech
$197.44 /

+13.87 (+7.56%)

AZN AstraZeneca
$54.58 /

+0.78 (+1.45%)

  • 21
    Jan
  • 23
    Jul
  • 19
    May
PFE Pfizer
$40.11 /

+0.54 (+1.36%)

NVAX Novavax
$166.90 /

-8.72 (-4.97%)

JNJ Johnson & Johnson
$170.66 /

+2.02 (+1.20%)

BNTX BioNTech
$197.44 /

+13.87 (+7.56%)

PFE Pfizer
$40.11 /

+0.54 (+1.36%)

NVAX Novavax
$166.90 /

-8.72 (-4.97%)

MRNA Moderna
$158.63 /

-4.51 (-2.76%)

JNJ Johnson & Johnson
$170.66 /

+2.02 (+1.20%)

INO Inovio
$6.98 /

+0.14 (+2.05%)

BNTX BioNTech
$197.44 /

+13.87 (+7.56%)

AZN AstraZeneca
$54.58 /

+0.78 (+1.45%)

PFE Pfizer
$40.11 /

+0.54 (+1.36%)

NVAX Novavax
$166.90 /

-8.72 (-4.97%)

MRNA Moderna
$158.63 /

-4.51 (-2.76%)

JNJ Johnson & Johnson
$170.66 /

+2.02 (+1.20%)

INO Inovio
$6.98 /

+0.14 (+2.05%)

BNTX BioNTech
$197.44 /

+13.87 (+7.56%)

AZN AstraZeneca
$54.58 /

+0.78 (+1.45%)

Friday
Conference/Events
Moderna participates in a conference call hosted by Truist » 09:25
05/07/21
05/07
09:25
05/07/21
09:25
MRNA

Moderna

$160.37 /

-2.31 (-1.42%)

Truist holds a conference…

Truist holds a conference call with management. on May 7 at 10 am.

ShowHide Related Items >><<
MRNA Moderna
$160.37 /

-2.31 (-1.42%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

05/07/21 Barclays
Moderna price target raised to $194 from $178 at Barclays
05/07/21 Goldman Sachs
Moderna price target raised to $228 from $206 at Goldman Sachs
05/06/21 Piper Sandler
Moderna price target lowered to $231 from $234 at Piper Sandler
05/06/21 Needham
Moderna execution 'continues to impress,' but reflected in stock, says Needham
MRNA Moderna
$160.37 /

-2.31 (-1.42%)

  • 19
    May
MRNA Moderna
$160.37 /

-2.31 (-1.42%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

Recommendations
Moderna price target raised to $194 from $178 at Barclays » 06:55
05/07/21
05/07
06:55
05/07/21
06:55
MRNA

Moderna

$160.37 /

-2.31 (-1.42%)

Barclays analyst Gena…

Barclays analyst Gena Wang raised the firm's price target on Moderna to $194 from $178 and keeps an Overweight rating on the shares following the Q1 results.

ShowHide Related Items >><<
MRNA Moderna
$160.37 /

-2.31 (-1.42%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

05/07/21 Goldman Sachs
Moderna price target raised to $228 from $206 at Goldman Sachs
05/06/21 Piper Sandler
Moderna price target lowered to $231 from $234 at Piper Sandler
05/06/21 Needham
Moderna execution 'continues to impress,' but reflected in stock, says Needham
05/05/21 Jefferies
Jefferies says COVID vaccine availability a supply-chain issue
MRNA Moderna
$160.37 /

-2.31 (-1.42%)

  • 19
    May
MRNA Moderna
$160.37 /

-2.31 (-1.42%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

Recommendations
Moderna price target raised to $228 from $206 at Goldman Sachs » 05:46
05/07/21
05/07
05:46
05/07/21
05:46
MRNA

Moderna

$160.37 /

-2.31 (-1.42%)

Goldman Sachs analyst…

Goldman Sachs analyst Salveen Richter raised the firm's price target on Moderna to $228 from $206 and keeps a Buy rating on the shares following the company's Q1 results. The analyst believes first booster data bodes well for Moderna's approach and views the World Trade Organization's proposal to waive intellectual property protections for Covid-19 vaccines as a likely "non-material issue" for the company. Moderna stated it will not enforce Covid-19 vaccine-related patents during the pandemic, says Richter, who notes the "immense" manufacturing know-how, resources and personnel requirements.

ShowHide Related Items >><<
MRNA Moderna
$160.37 /

-2.31 (-1.42%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

05/06/21 Piper Sandler
Moderna price target lowered to $231 from $234 at Piper Sandler
05/06/21 Needham
Moderna execution 'continues to impress,' but reflected in stock, says Needham
05/05/21 Jefferies
Jefferies says COVID vaccine availability a supply-chain issue
05/03/21 Piper Sandler
Piper reiterates $234 target on Moderna after WHO Emergency Use Listing
MRNA Moderna
$160.37 /

-2.31 (-1.42%)

  • 19
    May
MRNA Moderna
$160.37 /

-2.31 (-1.42%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

Conference/Events
Moderna participates in a conference call hosted by Truist » 04:55
05/07/21
05/07
04:55
05/07/21
04:55
MRNA

Moderna

$160.37 /

-2.31 (-1.42%)

Truist holds a conference…

Truist holds a conference call with management. on May 7 at 10 am.

ShowHide Related Items >><<
MRNA Moderna
$160.37 /

-2.31 (-1.42%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

05/06/21 Piper Sandler
Moderna price target lowered to $231 from $234 at Piper Sandler
05/06/21 Needham
Moderna execution 'continues to impress,' but reflected in stock, says Needham
05/05/21 Jefferies
Jefferies says COVID vaccine availability a supply-chain issue
05/03/21 Piper Sandler
Piper reiterates $234 target on Moderna after WHO Emergency Use Listing
MRNA Moderna
$160.37 /

-2.31 (-1.42%)

  • 19
    May
MRNA Moderna
$160.37 /

-2.31 (-1.42%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

Over a week ago
Recommendations
Moderna price target lowered to $231 from $234 at Piper Sandler » 19:13
05/06/21
05/06
19:13
05/06/21
19:13
MRNA

Moderna

$160.37 /

-2.31 (-1.42%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Moderna to $231 from $234 and keeps an Overweight rating on the shares after the company reported quarterly results. The analyst noted that concerns over the WHO patent waiver for COVID-19 vaccines continue to hit shares, though he does not think it would increase global vaccine supply due to complexity of manufacturing and scarcity of raw materials.

ShowHide Related Items >><<
MRNA Moderna
$160.37 /

-2.31 (-1.42%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

05/06/21 Needham
Moderna execution 'continues to impress,' but reflected in stock, says Needham
05/05/21 Jefferies
Jefferies says COVID vaccine availability a supply-chain issue
05/03/21 Piper Sandler
Piper reiterates $234 target on Moderna after WHO Emergency Use Listing
04/29/21 Piper Sandler
Piper keeps $234 target on Moderna after raised Covid vaccine guidance
MRNA Moderna
$160.37 /

-2.31 (-1.42%)

  • 19
    May
MRNA Moderna
$160.37 /

-2.31 (-1.42%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

On The Fly
Fly Intel: Wall Street's top stories for Thursday » 17:44
05/06/21
05/06
17:44
05/06/21
17:44
UBER

Uber

$46.64 /

-4.57 (-8.92%)

, PYPL

PayPal

$251.87 /

+4.23 (+1.71%)

, ETSY

Etsy

$157.73 /

-27.05 (-14.64%)

, MRNA

Moderna

$160.37 /

-2.31 (-1.42%)

, HOME

At Home Group

$37.74 /

+6.49 (+20.77%)

, LKCO

Luokung Technology

$1.68 /

+0.195 (+13.18%)

, SBH

Sally Beauty

$24.29 /

+4.015 (+19.80%)

, PCT

PureCycle Technologies

$14.85 /

-9.78 (-39.71%)

, JRVR

James River Group

$34.24 /

-12.33 (-26.48%)

Equity index futures were…

ShowHide Related Items >><<
UBER Uber
$46.64 /

-4.57 (-8.92%)

SBH Sally Beauty
$24.29 /

+4.015 (+19.80%)

PYPL PayPal
$251.87 /

+4.23 (+1.71%)

PCT PureCycle Technologies
$14.85 /

-9.78 (-39.71%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

LKCO Luokung Technology
$1.68 /

+0.195 (+13.18%)

JRVR James River Group
$34.24 /

-12.33 (-26.48%)

HOME At Home Group
$37.74 /

+6.49 (+20.77%)

ETSY Etsy
$157.73 /

-27.05 (-14.64%)

UBER Uber
$46.64 /

-4.57 (-8.92%)

05/07/21 Truist
James River Group upgraded to Buy from Hold at Truist
05/06/21 Wedbush
Uber price target lowered to $66 from $76 at Wedbush
05/06/21 JPMorgan
JPMorgan boosts Uber target to $74 on continued mobility recovery
05/06/21 Deutsche Bank
Uber price target raised to $85 from $82 at Deutsche Bank
PYPL PayPal
$251.87 /

+4.23 (+1.71%)

05/07/21 BMO Capital
PayPal price target raised to $256 from $241 at BMO Capital
05/07/21 Oppenheimer
PayPal price target raised to $322 from $310 at Oppenheimer
05/06/21 Oppenheimer
PayPal price target raised to $322 from $310 at Oppenheimer
05/06/21 Credit Suisse
PayPal price target raised to $315 from $310 at Credit Suisse
ETSY Etsy
$157.73 /

-27.05 (-14.64%)

05/07/21 Stifel
Etsy upgraded to Buy from Hold at Stifel
05/06/21 Canaccord
Etsy recent selloff an attractive buying opportunity, says Canaccord
05/06/21 Wedbush
Etsy price target lowered to $204 from $250 at Wedbush
05/06/21 Oppenheimer
Etsy price target lowered to $200 from $240 at Oppenheimer
MRNA Moderna
$160.37 /

-2.31 (-1.42%)

05/07/21 Barclays
Moderna price target raised to $194 from $178 at Barclays
05/07/21 Goldman Sachs
Moderna price target raised to $228 from $206 at Goldman Sachs
05/06/21 Piper Sandler
Moderna price target lowered to $231 from $234 at Piper Sandler
05/06/21 Needham
Moderna execution 'continues to impress,' but reflected in stock, says Needham
HOME At Home Group
$37.74 /

+6.49 (+20.77%)

05/07/21 Craig-Hallum
At Home Group downgraded to Hold from Buy at Craig-Hallum
05/07/21 Craig-Hallum
At Home Group downgraded to Hold from Buy at Craig-Hallum
05/06/21 Wells Fargo
At Home Group price target raised to $37 from $30 at Wells Fargo
03/25/21 Loop Capital
At Home Group price target raised to $27 from $20 at Loop Capital
LKCO Luokung Technology
$1.68 /

+0.195 (+13.18%)

SBH Sally Beauty
$24.29 /

+4.015 (+19.80%)

03/11/21 Oppenheimer
Sally Beauty downgraded to Perform from Outperform at Oppenheimer
01/21/21 Oppenheimer
Oppenheimer upgrades 'uniquely positioned' Freshpet to Outperform
01/20/21 Morgan Stanley
Sally Beauty upgraded to Equal Weight from Underweight at Morgan Stanley
06/04/20 Oppenheimer
Sally Beauty upgraded to Outperform at Oppenheimer
PCT PureCycle Technologies
$14.85 /

-9.78 (-39.71%)

04/21/21 Roth Capital
PureCycle Technologies initiated with a Buy at Roth Capital
03/18/21 Craig-Hallum
PureCycle Technologies initiated with a Buy at Craig-Hallum
JRVR James River Group
$34.24 /

-12.33 (-26.48%)

05/07/21 Truist
James River Group upgraded to Buy from Hold at Truist
04/13/21 Truist
James River Group price target raised to $56 from $52 at Truist
01/06/21 Compass Point
James River Group price target raised to $69 from $56 at Compass Point
UBER Uber
$46.64 /

-4.57 (-8.92%)

SBH Sally Beauty
$24.29 /

+4.015 (+19.80%)

PYPL PayPal
$251.87 /

+4.23 (+1.71%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

JRVR James River Group
$34.24 /

-12.33 (-26.48%)

HOME At Home Group
$37.74 /

+6.49 (+20.77%)

ETSY Etsy
$157.73 /

-27.05 (-14.64%)

  • 06
    May
  • 08
    Jan
  • 06
    Nov
  • 19
    May
UBER Uber
$46.64 /

-4.57 (-8.92%)

PYPL PayPal
$251.87 /

+4.23 (+1.71%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

ETSY Etsy
$157.73 /

-27.05 (-14.64%)

UBER Uber
$46.64 /

-4.57 (-8.92%)

SBH Sally Beauty
$24.29 /

+4.015 (+19.80%)

PYPL PayPal
$251.87 /

+4.23 (+1.71%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

LKCO Luokung Technology
$1.68 /

+0.195 (+13.18%)

HOME At Home Group
$37.74 /

+6.49 (+20.77%)

UBER Uber
$46.64 /

-4.57 (-8.92%)

PYPL PayPal
$251.87 /

+4.23 (+1.71%)

PCT PureCycle Technologies
$14.85 /

-9.78 (-39.71%)

MRNA Moderna
$160.37 /

-2.31 (-1.42%)

JRVR James River Group
$34.24 /

-12.33 (-26.48%)

ETSY Etsy
$157.73 /

-27.05 (-14.64%)

Recommendations
Moderna execution 'continues to impress,' but reflected in stock, says Needham » 15:08
05/06/21
05/06
15:08
05/06/21
15:08
MRNA

Moderna

$159.34 /

-3.34 (-2.05%)

After Moderna announced…

After Moderna announced its first profitable quarter this morning, Needham analyst Joseph Stringer said the company's "execution in all phases of the COVID vaccine program continues to impress" and that the interim positive results from a COVID trial in adolescents gives him added confidence in driving vaccinations in younger people. However, he believes COVID vaccine expectations are fully reflected in the stock price and he keeps a Hold rating on the shares.

ShowHide Related Items >><<
MRNA Moderna
$159.34 /

-3.34 (-2.05%)

MRNA Moderna
$159.34 /

-3.34 (-2.05%)

05/05/21 Jefferies
Jefferies says COVID vaccine availability a supply-chain issue
05/03/21 Piper Sandler
Piper reiterates $234 target on Moderna after WHO Emergency Use Listing
04/29/21 Piper Sandler
Piper keeps $234 target on Moderna after raised Covid vaccine guidance
MRNA Moderna
$159.34 /

-3.34 (-2.05%)

  • 19
    May
MRNA Moderna
$159.34 /

-3.34 (-2.05%)

MRNA Moderna
$159.34 /

-3.34 (-2.05%)

MRNA Moderna
$159.34 /

-3.34 (-2.05%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.